CytomX Therapeutics, Inc.
CTMXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 19, 2026 | Wolfe Research | $6.00(+71%) | $3.50 | TheFly | |
| May 11, 2026 | H.C. Wainwright | $11.00(+176%) | $3.98 | TheFly | |
| Mar 18, 2026 | Jefferies | Roger Song | $16.00(+247%) | $4.61 | StreetInsider |
| Mar 16, 2026 | Oppenheimer | Matthew Biegler | $12.00(+50%) | $8.03 | StreetInsider |
| Feb 4, 2026 | Barclays | $10.00(+65%) | $6.07 | TheFly | |
| Jan 20, 2026 | Piper Sandler | $10.00(+86%) | $5.39 | TheFly | |
| Jan 20, 2026 | Guggenheim | Michael Schmidt | $10.00(+86%) | $5.39 | TheFly |
| Jan 20, 2026 | Barclays | Etzer Darout | $8.00(+48%) | $5.39 | TheFly |
| Oct 21, 2025 | Barclays | Etzer Darout | $6.00(+60%) | $3.74 | TheFly |
| Sep 16, 2025 | Barclays | Etzer Darout | $3.50(+79%) | $1.96 | TheFly |
| Jul 31, 2025 | Oppenheimer | Matthew Biegler | $7.00(+202%) | $2.32 | TheFly |
| Nov 8, 2024 | BMO Capital | Etzer Darout | $3.68(+238%) | $1.09 | StreetInsider |
| Nov 8, 2024 | Piper Sandler | Joseph Catanzaro | $3.25(+198%) | $1.09 | StreetInsider |
| Aug 9, 2024 | BMO Capital | Etzer Darout | $3.56(+202%) | $1.18 | StreetInsider |
| May 27, 2024 | Piper Sandler | Joseph Catanzaro | $3.50(+100%) | $1.75 | TheFly |
| May 9, 2024 | BMO Capital | Etzer Darout | $3.59(-14%) | $4.19 | StreetInsider |
| May 9, 2024 | Wedbush | Robert Driscoll | $8.00(+233%) | $2.40 | StreetInsider |
| May 5, 2024 | Jefferies | Roger Song | $8.00(+80%) | $4.46 | TheFly |
| Mar 12, 2024 | Jefferies | Roger Song | $2.50(+16%) | $2.15 | StreetInsider |
| Mar 12, 2024 | BMO Capital | Etzer Darout | $3.25(+51%) | $2.15 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wedbush | maintain | Outperform | Nov 6, 2026 |
| JP Morgan | maintain | Overweight | Aug 13, 2026 |
| Guggenheim | maintain | Buy | Aug 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 11, 2026 |
| Piper Sandler | maintain | Overweight | Mar 23, 2026 |
| Barclays | maintain | Overweight | Mar 19, 2026 |
| Guggenheim | maintain | Buy | Mar 18, 2026 |
| Jefferies | maintain | Buy | Mar 18, 2026 |
| Wedbush | maintain | Outperform | Mar 17, 2026 |
| JP Morgan | upgrade | Neutral →Overweight | Mar 16, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 16, 2026 |
| Guggenheim | maintain | Buy | Mar 9, 2026 |
| Barclays | maintain | Overweight | Feb 4, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Feb 4, 2026 |
| Piper Sandler | maintain | Overweight | Jan 20, 2026 |
| Barclays | maintain | Overweight | Jan 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2025 |
| Barclays | maintain | Overweight | Oct 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 20, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | May 15, 2025 |
| Piper Sandler | maintain | Overweight | May 15, 2025 |
| Piper Sandler | maintain | Overweight | Apr 14, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Mar 7, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Jan 7, 2025 |
| Piper Sandler | upgrade | Neutral →Overweight | May 28, 2024 |
Earnings History
Next report: Feb 24, 2027 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.09 | $-0.07 | $1.7M | $10.4M |
| Aug 6, 2026 | $-0.09 | $-0.08 | $1.4M | $12.4M |
| May 7, 2026 | $-0.10 | $-0.14 | $10.3M | $4.7M |
| Mar 16, 2026 | $-0.22 | $-0.08 | $661.0K | $7.3M |
| Nov 6, 2025 | $-0.09 | $-0.05 | $6.0M | $7.3M |
| Aug 7, 2025 | $-0.00 | $-0.06 | $18.7M | $18.3M |
| May 12, 2025 | $0.27 | $0.12 | $50.9M | $35.4M |
| Mar 6, 2025 | $0.22 | $-0.23 | $38.1M | $13.0M |
News
CytomX Therapeutics, Inc. ( CTMX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Chris Ogden - SVP, CFO & Secretary Sean McCarthy - Chairman & CEO Conference Call Participants Paul Jeng - Guggenheim Securities, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Nabeel Nissar - Jefferies LLC, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator G…
CytomX Therapeutics NASDAQ: CTMX plans to provide a January update on its lead cancer drug candidate, Varseta-M, as it prepares for a potential registrational study in metastatic colorectal cancer in the first half of 2027.
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.09 per share a year ago.
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study in 2L mCRC expected to be initiated by year-end - - Phase 1 Varseta-M monotherapy expansion cohorts for gastric and gastroesophageal junction (GEJ) cancer, EpCAM-sel…
CytomX Therapeutics is rated Buy, driven by positive clinical data for Varseta-M and a robust $367M cash runway after significant dilution. Varseta-M, targeting late-line colorectal cancer, achieved 20–32% ORR and 7 months PFS, securing FDA Fast Track and pivotal trial initiation in 1H 2027. Strategic partnerships with Amgen, Regeneron, and Moderna validate the PROBODY platform, with $6.7B in potential milestones, though legacy partnership terminations pressured revenue.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in November.
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 5, 2026, after the close of U.S. markets.
CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) shares reached a new 52-week low on Wednesday. The company traded as low as $2.32 and last traded at $2.33, with a volume of 5,223,013 shares traded. The stock had previously closed at $2.42. Analysts Set New Price Targets CTMX has been the topic of several analyst
CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in September.
- Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in 1H 2027 - SOUTH SAN FRANCISCO, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Varseta-M fo…
AWM Investment Company Inc. acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ: CTMX) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor acquired 150,000 shares of the biotechnology company's stock, valued at approximately $562,000. AWM Investment Company Inc. owned 0.07% of CytomX Therapeutics at the
Bank of America Corp DE boosted its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 1,064.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,202,785 shares of the biotechnology company's stock after purchasing an additional 9,326,480 shares during the quarter. Bank
CTMX has the PROBODY platform, which I think potentially unlocks difficult oncology targets by limiting drug activity in healthy tissue. Their lead asset is Varseta-M, which has interesting early colorectal cancer activity. Yet, it still requires larger and more mature datasets. CTMX's pipeline has lined up a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts. These are several catalysts through 1H2027.